Trial Profile
A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 May 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Methylprednisolone; Methylprednisolone
- Indications Membranous glomerulonephritis
- Focus Therapeutic Use
- Acronyms RI-CYCLO
- 16 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 16 May 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Jan 2017 New trial record